Status:
COMPLETED
A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination
Lead Sponsor:
University of Oxford
Conditions:
Tuberculosis
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This is a human pilot study of 16 healthy BCG-naïve volunteers to quantify BCG from the BCG vaccination site. Volunteers will be vaccinated with BCG. The first 8 will go on to have a punch biopsy and ...
Detailed Description
Over the last 3 years, the McShane group in Oxford have established a clinical trial programme to evaluate the safety and immunogenicity of this BCG prime-MVA85A boost vaccination strategy in a series...
Eligibility Criteria
Inclusion
- Subject is willing and able to give informed consent for participation in the study
- Male or Female, aged 18 to 50 years
- In good health
- BCG-naïve
- Screening elispot negative (less than 17 spot forming cells per million PBMC) for ESAT 6 and CFP 10 peptide pools
- Resident in or near Oxford for the duration of the study
- Female patient/subjects of child bearing potential must be willing to ensure that they practice effective contraception use during the study.
- Subject has clinically acceptable laboratory results from Pre Study Screen
- Able (in the Investigators opinion) and willing to comply with all study requirements
- Willing to allow his or her General Practitioner to be notified of participation in the study
Exclusion
- Previous BCG vaccination
- Female subject who is pregnant, lactating or planning pregnancy during the course of the study
- Persons suffering from malignant conditions (e.g., lymphoma, leukaemia, Hodgkin's disease or other tumours of the reticulo-endothelial system), primary or secondary immunodeficiencies, HIV infection, or moderate/severe dermatological conditions
- Administration of chronic (defined as more than 14 days) immunosuppressive drugs or other immune modifying drugs within six months of vaccination. (For corticosteroids, this will mean prednisolone, or equivalent, ≥ 0.5 mg/kg/day. Inhaled and topical steroids are allowed)
- Any history of severe allergic reaction or anaphylaxis in reaction to vaccination
- Administration of immunoglobulins or donation of blood products during the study or within the past 12 weeks
- Suspected or known current drug and/or alcohol abuse (as defined by an alcohol intake of \>42 units a week)
- Any on-going chronic illness requiring hospital specialist supervision
- Any other significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or may influence the result of the study, or the subject's ability to participate in the study.
- Subjects who have participated in another research study involving an investigational product in the past 12 weeks
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00653627
Start Date
August 1 2007
End Date
April 1 2010
Last Update
July 1 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CCVTM, University of Oxford
Oxford, United Kingdom, OX3 7LJ